This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Zydus, Lupin Co-Market Semaglutide in India
Business licensing agreement

Zydus, Lupin Co-Market Semaglutide in India

Analysis based on 8 articles · First reported Mar 17, 2026 · Last updated Mar 17, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration between Astec LifeSciences and Lupin (company) is expected to positively impact the Indian pharmaceutical market by increasing access to advanced diabetes and weight management therapies. This strategic move, ahead of the innovator molecule's patent expiry, positions both companies to strengthen their market presence and potentially drive growth in the GLP-1 segment.

Pharmaceuticals Biotechnology
Event Summary

Astec LifeSciences and Lupin (company) have formed a licensing and supply agreement to co-market Semaglutide Injection in India. This partnership aims to expand access to advanced therapies for type 2 diabetes and chronic weight management, utilizing a patient-friendly reusable pen device. Under the agreement, Lupin (company) will have semi-exclusive rights to market the drug under the brand names Semanext and Livarise, while Astec LifeSciences will continue to market it as Semaglyn, Mashema, and Altermet. Lupin (company) will pay Astec LifeSciences upfront licensing fees and milestone payments. Both companies anticipate strengthening their presence in India's growing market for metabolic therapies, especially as the patent for the innovator molecule is expected to expire soon, opening the market to broader competition.

Entities Involved
stock
Lupin (company)
Lupin (company) entered a licensing and supply agreement with Astec LifeSciences to co-market Semaglutide Injection in India, gaining semi-exclusive rights to distribute the drug under its own brand names. This enhances its diabetes portfolio and strengthens its commitment to advanced cardio-metabolic treatments.
Importance 100.0 Sentiment 70.0
per
Nilesh Gupta
Nilesh Gupta, Managing Director of Lupin (company), emphasized the significance of the partnership in strengthening Lupin (company)'s cardio-metabolic portfolio and expanding patient access in India.
Importance 50.0 Sentiment 0.0
per
Sharvil Patel
Sharvil Patel, Managing Director of Astec LifeSciences, highlighted the patient-centric innovation of the pen device and expressed pleasure in partnering with Lupin (company) to broaden access to the medicine.
Importance 50.0 Sentiment 0.0
stock
Astec LifeSciences
Importance 0.0 Sentiment 0.0
stock
Sun Pharma
Importance 0.0 Sentiment 0.0
stock
Abbott Laboratories
Importance 0.0 Sentiment 0.0
cnt
India
Importance 0.0 Sentiment 0.0
Relationships
Lupin (company) related ↔ India
Astec LifeSciences competitor ↔ Sun Pharma Astec LifeSciences, alongside its associated life sciences brands, operates as an industry peer and competitor to Sun Ph
Astec LifeSciences unrelated ↔ Abbott Laboratories Astec LifeSciences does not have a direct business relationship with Abbott Laboratories.
Astec LifeSciences related ↔ India
Sun Pharma competitor ↔ Abbott Laboratories Sun Pharmaceutical Industries acts as a major competitor to Abbott Laboratories across various therapeutic segments and
Sun Pharma related ↔ India
Abbott Laboratories related ↔ India
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.